Beijing Hotgen Biotech Co Ltd (SHG:688068) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Hotgen Biotech Co Ltd (688068)
Beijing Hotgen Biotech Co Ltd (SHG:688068) has a market capitalization of $1.31 Billion (CN¥8.96 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #7826 globally and #1776 in its home market, demonstrating a 6.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Hotgen Biotech Co Ltd's stock price CN¥96.65 by its total outstanding shares 92707940 (92.71 Million). Also see Beijing Hotgen Biotech Co Ltd assets under control for a full breakdown of the balance sheet.
Beijing Hotgen Biotech Co Ltd Market Cap History: 2019 to 2026
Beijing Hotgen Biotech Co Ltd's market capitalization history from 2019 to 2026. Data shows growth from $400.40 Million to $1.31 Billion (11.72% CAGR). Also see Beijing Hotgen Biotech Co Ltd (688068) cash conversion ratio for how efficiently the company converts equity into cash flow.
Beijing Hotgen Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Hotgen Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 688068 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.64x
Beijing Hotgen Biotech Co Ltd's market cap is 1.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $400.40 Million | $210.41 Million | $33.88 Million | 1.90x | 11.82x |
| 2020 | $334.16 Million | $513.53 Million | $112.07 Million | 0.65x | 2.98x |
| 2021 | $1.00 Billion | $5.37 Billion | $2.19 Billion | 0.19x | 0.46x |
| 2022 | $826.17 Million | $3.56 Billion | $944.74 Million | 0.23x | 0.87x |
| 2023 | $556.89 Million | $547.84 Million | $28.92 Million | 1.02x | 19.25x |
| 2024 | $838.93 Million | $510.90 Million | -$191.00 Million | 1.64x | N/A |
Competitor Companies of 688068 by Market Capitalization
Companies near Beijing Hotgen Biotech Co Ltd in the global market cap rankings as of September 24, 2026. Review 688068 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Beijing Hotgen Biotech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Beijing Hotgen Biotech Co Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, Beijing Hotgen Biotech Co Ltd's market cap moved from $400.40 Million to $ 1.31 Billion, with a yearly change of 11.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.31 Billion | -40.34% |
| 2025 | CN¥2.20 Billion | +161.97% |
| 2024 | CN¥838.93 Million | +50.65% |
| 2023 | CN¥556.89 Million | -32.59% |
| 2022 | CN¥826.17 Million | -17.70% |
| 2021 | CN¥1.00 Billion | +200.40% |
| 2020 | CN¥334.16 Million | -16.54% |
| 2019 | CN¥400.40 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Beijing Hotgen Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.31 Billion USD |
| MoneyControl | $1.31 Billion USD |
| MarketWatch | $1.31 Billion USD |
| marketcap.company | $1.31 Billion USD |
| Reuters | $1.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more